La Jolla Pharmaceutical Co. (LJPC)

32.15
NASDAQ : Health Technology
Prev Close 32.61
Day Low/High 30.70 / 32.77
52 Wk Low/High 17.26 / 41.36
Avg Volume 539.60K
Exchange NASDAQ
Shares Outstanding 22.12M
Market Cap 727.42M
EPS -4.50
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

First Week of LJPC February 16th Options Trading

Investors in La Jolla Pharmaceutical Co. saw new options become available this week, for the February 16th expiration.

Relative Strength Alert For La Jolla Pharmaceutical

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Notable Friday Option Activity: LJPC, BANC, SIEN

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in La Jolla Pharmaceutical Co. , where a total of 2,618 contracts have traded so far, representing approximately 261,800 underlying shares.

La Jolla Pharmaceutical Company Announces Financial Results For The Three And Nine Months Ended September 30, 2017 And Recent Corporate Progress

La Jolla Pharmaceutical Company Announces Financial Results For The Three And Nine Months Ended September 30, 2017 And Recent Corporate Progress

La Jolla Pharmaceutical Company (NASDAQ: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening...

Commit To Purchase La Jolla Pharmaceutical Co. At $25, Earn 14.7% Annualized Using Options

Investors considering a purchase of La Jolla Pharmaceutical Co. stock, but tentative about paying the going market price of $34.75/share, might benefit from considering selling puts among the alternative strategies at their disposal.

La Jolla Pharmaceutical Company Announces Intent To Submit Marketing Authorization Application For LJPC-501 In The Third Quarter Of 2018

La Jolla Pharmaceutical Company Announces Intent To Submit Marketing Authorization Application For LJPC-501 In The Third Quarter Of 2018

La Jolla Pharmaceutical Company (NASDAQ:LJPC) (the Company or La Jolla) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued favorable Scientific...

Prespecified Analysis Of ATHOS-3 Indicates Survival Benefit In LJPC-501-Treated Patients With Relatively Low Angiotensin II State

Prespecified Analysis Of ATHOS-3 Indicates Survival Benefit In LJPC-501-Treated Patients With Relatively Low Angiotensin II State

La Jolla Pharmaceutical Company (NASDAQ: LJPC) (the Company or La Jolla) today announced an abstract entitled "Baseline angiotensin levels and ACE effects in patients with vasodilatory shock treated with angiotensin...

La Jolla Pharmaceutical Company Announces U.S. FDA Acceptance Of New Drug Application For LJPC-501

La Jolla Pharmaceutical Company Announces U.S. FDA Acceptance Of New Drug Application For LJPC-501

La Jolla Pharmaceutical Company (NASDAQ: LJPC) (the Company or La Jolla) today announced that the U.

La Jolla Pharmaceutical Company Announces Launch Of Expanded Access Program For LJPC-501

La Jolla Pharmaceutical Company Announces Launch Of Expanded Access Program For LJPC-501

La Jolla Pharmaceutical Company (NASDAQ: LJPC) (the Company or La Jolla), today announced that the Company has initiated an expanded access program (EAP) in the United States to provide its investigational drug,...

La Jolla Pharmaceutical Company Announces Financial Results For The Three And Six Months Ended June 30, 2017 And Recent Corporate Progress

La Jolla Pharmaceutical Company Announces Financial Results For The Three And Six Months Ended June 30, 2017 And Recent Corporate Progress

La Jolla Pharmaceutical Company (NASDAQ: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening...

Commit To Purchase La Jolla Pharmaceutical Co. At $24, Earn 17.3% Annualized Using Options

Commit To Purchase La Jolla Pharmaceutical Co. At $24, Earn 17.3% Annualized Using Options

Investors eyeing a purchase of La Jolla Pharmaceutical Co. shares, but tentative about paying the going market price of $31.41/share, might benefit from considering selling puts among the alternative strategies at their disposal.

Mixed Outcomes for La Jolla Pharma Shock Drug Fuels Debate Over Sales Potential

Mixed Outcomes for La Jolla Pharma Shock Drug Fuels Debate Over Sales Potential

LJPC-501 reversed dangerously low blood pressure in patients suffering from a severe form of shock, but the drug did not improve total organ function or reduce mortality.

Results Of ATHOS-3 Phase 3 Study Of LJPC-501 Published In The New England Journal Of Medicine

La Jolla Pharmaceutical Company (Nasdaq: LJPC) (La Jolla) today announced that results of the ATHOS-3 ( Angiotensin II for the Treatment of High- Output Shock) Phase 3 study of LJPC-501 (angiotensin II) have been...

6 Hot Unusual Volume Setups

6 Hot Unusual Volume Setups

Here's a technical look at how to play six stocks trending higher with unusual volume flows.

Short Interest Makes 11% Move For LJPC

The most recent short interest data has been released for the 04/28/2017 settlement date, which shows a 505,133 share increase in total short interest for La Jolla Pharmaceutical Co. , to 5,069,906, an increase of 11.07% since 04/13/2017.

La Jolla Pharmaceutical Enters Oversold Territory (LJPC)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

La Jolla Pharmaceutical Company Announces Financial Results For The Three Months Ended March 31, 2017 And Recent Corporate Progress

La Jolla Pharmaceutical Company (NASDAQ: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening...

Short Interest Makes 24% Move For LJPC

The most recent short interest data has been released for the 04/13/2017 settlement date, which shows a 881,552 share increase in total short interest for La Jolla Pharmaceutical Co. , to 4,564,773, an increase of 23.93% since 03/31/2017.

Short Interest Makes 103.8% Move For LJPC

The most recent short interest data has been released for the 03/15/2017 settlement date, which shows a 1,829,419 share increase in total short interest for La Jolla Pharmaceutical Co. , to 3,591,287, an increase of 103.83% since 02/28/2017.

La Jolla Pharmaceutical Company Announces Pricing Of Public Offering Of Common Stock

La Jolla Pharmaceutical Company (Nasdaq: LJPC) ("La Jolla" or the "Company"), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening...

La Jolla Pharmaceutical Company Announces Proposed Underwritten Public Offering Of Common Stock

La Jolla Pharmaceutical Company (Nasdaq: LJPC) ("La Jolla" or the "Company), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening...

Insider Bets Paying Off At LJPC As New 52-Week High Reached

In trading on Monday, shares of La Jolla Pharmaceutical Co. touched a new 52-week high of $39.28/share.

Biotechs Remain the Best Place For Stock Picking

Biotechs Remain the Best Place For Stock Picking

Biotech companies show more energy than the rest of the market Monday.

6 Stocks with Unusual Volume Activity

6 Stocks with Unusual Volume Activity

When stocks move with unusual volume, it can signal insider buying and selling.

6 Stocks on the Move With Unusual Volume

6 Stocks on the Move With Unusual Volume

Here's a technical look at how to trade a number of stocks rising with unusual volume flow.